ARTA
NBSE

A.R.T. Advisors’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

A.R.T. Advisors’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-104
Closed -$34K – 1794
2017
Q1 		$34K Buy
+104
New +$48.2K ﹤0.01% 1352
2016
Q3 		– Sell
-142
Closed -$155K – 1237
2016
Q2 		$155K Sell
142
-132
-48% -$166K 0.01% 1150
2016
Q1 		$351K Sell
274
-73
-21% -$104K 0.02% 993
2015
Q4 		$851K Buy
+347
New +$533K 0.04% 645
2015
Q3 		– Sell
-141
Closed -$141K – 1657
2015
Q2 		$141K Buy
141
+61
+76% +$65.8K ﹤0.01% 1326
2015
Q1 		$81K Buy
+80
New +$264K ﹤0.01% 1333

Other funds holding NBSE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

A.R.T. Advisors's NBSE Position: Q2 2017 in Review

A.R.T. Advisors sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2017, closing a stake of 104 shares — an estimated $34K sold.

A.R.T. Advisors first reported a position in NBSE in Q1 2015 and held it in 6 quarters. The position peaked at $851K in Q4 2015. 38 funds tracked by Wall St. Rank hold NBSE as of Q2 2017.

  • A.R.T. Advisors reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • A.R.T. Advisors sold 104 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2017, an estimated $34K.
  • A.R.T. Advisors first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2015 and held it in 6 quarters.
  • A.R.T. Advisors's NeuBase Therapeutics, Inc. Common Stock position peaked at $851K in Q4 2015.
  • 38 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2017.

Based on A.R.T. Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.